STOCK TITAN

ClearPoint Neuro raises stock sales agreement cap to $150M

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
8-K

Rhea-AI Filing Summary

ClearPoint Neuro, Inc. amended its at-the-market sales agreement with Stifel, Nicolaus & Company, Incorporated, increasing the agreement’s aggregate sales-proceeds limit from $50 million to $150 million, inclusive of proceeds from sales under the original agreement.

The amendment does not increase the amount available under the current prospectus supplement: approximately $27.5 million remains available for offer and sale. As of November 18, 2026, approximately $22.5 million had been sold under the original agreement. Sales beyond the current amount require another prospectus supplement. The company is not obligated to sell shares and may suspend offers; the agent may receive a commission of up to 3.0% of gross sales price.

Item 1.01 Entry into a Material Definitive Agreement Business
The company signed a significant contract such as a merger agreement, credit facility, or major partnership.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Aggregate sales-proceeds limit $150 million Amended at-the-market sales agreement; includes proceeds from sales under the original agreement.
Previous aggregate sales-proceeds limit $50 million Limit under the original sales agreement before the amendment.
Shares sold under original agreement Approximately $22.5 million As of November 18, 2026.
Amount available under current prospectus supplement Approximately $27.5 million As of November 18, 2026; unchanged by the amendment.
Sales agent commission Up to 3.0% of gross sales price Applies to shares sold under the sales agreement.
at-the-market offering financial
"sell shares through an “at the market offering” program"
An at-the-market offering is a method companies use to sell new shares of stock directly into the open market over time, rather than all at once. This allows them to raise money gradually, similar to selling small pieces of a product instead of a large batch. For investors, it means the company can access funding more flexibly, but it may also increase the supply of shares and influence the stock’s price.
prospectus supplement regulatory
"the related prospectus supplement dated November 7, 2024"
A prospectus supplement is an additional document provided alongside a company's main offering details, offering updated or extra information about a specific financial product being sold. It helps investors understand the latest terms, risks, and details of the investment, similar to how an update or revision clarifies or expands on original instructions, ensuring they have current and complete information before making a decision.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How much can ClearPoint Neuro (CLPT) sell under the amended ATM agreement?

The agreement’s aggregate sales-proceeds limit is $150 million, inclusive of sales under the original agreement. The previous limit was $50 million. The current prospectus supplement’s available amount remains approximately $27.5 million.

How much remains available under ClearPoint Neuro’s (CLPT) current ATM prospectus supplement?

Approximately $27.5 million remains available for offer and sale under the current prospectus supplement. The amount was not increased by the amendment, and sales above it require another prospectus supplement.

What commission may the sales agent receive under ClearPoint Neuro’s (CLPT) ATM agreement?

The sales agent may receive a commission of up to 3.0% of the gross sales price of shares sold under the agreement.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
0001285550false00012855502026-11-182026-11-18

 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 18, 2026

 

 

CLEARPOINT NEURO, INC.

(Exact name of Registrant as Specified in Its Charter)

 

 

Delaware

001-34822

58-2394628

(State or Other Jurisdiction
of Incorporation)

(Commission File Number)

(IRS Employer
Identification No.)

 

 

 

120 S. Sierra Ave., Suite 100

 

Solana Beach, California

 

92075

(Address of Principal Executive Offices)

 

(Zip Code)

 

Registrant’s Telephone Number, Including Area Code: 888 287-9109

 

 

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class

 

Trading
Symbol(s)

 


Name of each exchange on which registered

Common Stock, $0.01 par value per share

 

CLPT

 

The Nasdaq Stock Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 


 

Item 1.01 Entry into a Material Definitive Agreement.

In November 2024, ClearPoint Neuro, Inc. (the “Company”) entered into an At-The-Market Equity Offering Sales Agreement (the “Original Sales Agreement”) with Stifel, Nicolaus & Company, Incorporated, as sales agent (the “Agent”), to sell shares of the Company’s common stock having aggregate sales proceeds of up to $50 million (the “Shares”), from time to time, through an “at the market offering” program, as defined in Rule 415(a)(4) under the Securities Act of 1933, as amended (the “Securities Act”).

On November 18, 2026, the Company and the Agent entered into an amendment to the Original Sales Agreement (the “Sales Agreement Amendment,” and collectively with the Original Sales Agreement, the “Sales Agreement”) to increase the amount of aggregate sales proceeds from sales of shares of the Company’s common stock thereunder from $50,000,000 to $150,000,000, inclusive of the aggregate sales proceeds from sales of shares of the Company’s common stock under the Original Sales Agreement.

As of the date of this report, the Company has sold approximately $22.5 million of shares of its common stock under the Original Sales Agreement pursuant to the Company’s registration statement on Form S-3 (File No. 333-275476), which was declared effective by the Securities and Exchange Commission (“SEC”) on November 20, 2023 (the “Existing Registration Statement”), the base prospectus filed as part thereof and the related prospectus supplement dated November 7, 2024 and filed with the SEC on November 7, 2024 (the “ATM Prospectus Supplement”). The amount of shares of the Company’s common stock available for offer and sale under the ATM Prospectus Supplement is not being increased from the amount currently available for offer and sale thereunder, which is approximately $27.5 million as of the date of this report. If the Company desires to offer and sell any additional amount of shares of the Company’s common stock under the Existing Registration Statement in excess of the approximately $27.5 million available for offer and sale under the ATM Prospectus Supplement, the Company will file a prospectus supplement to the Existing Registration Statement.

Subject to the terms and conditions of the Sales Agreement, the Agent will use commercially reasonable efforts, consistent with its normal trading and sales practices, applicable state and federal laws, rules and regulations, and the rules of the Nasdaq Capital Market, to sell the Shares from time to time based upon the Company’s instructions for the sales, including any price, time or size limits specified by the Company. Under the Sales Agreement, the Agent may sell the Shares by any method deemed to be an “at the market offering” as defined in Rule 415(a)(4) under the Securities Act. The Agent’s obligations to sell the Shares under the Sales Agreement are subject to satisfaction of certain conditions, including customary closing conditions.

The Company has agreed to pay Agent a commission of up to 3.0% of the gross sales price of the Shares for amounts of Shares sold from time to time pursuant to the Sales Agreement and to provide Agent with customary indemnification and contribution rights, including for liabilities under the Securities Act. The Company also will reimburse the Agent for certain specified expenses in connection with entering into the Sales Agreement. The Sales Agreement contains customary representations and warranties and conditions to the placements of the Shares pursuant thereto. The Company is not obligated to sell any Shares under the Sales Agreement and may at any time suspend solicitation and offers under the Sales Agreement. The Sales Agreement may be terminated by the Company at any time by giving written notice to the Sales Agent for any reason or by the Sales Agent at any time by giving written notice to the Company for any reason or immediately under certain circumstances, and shall automatically terminate upon the issuance and sale of all Shares.

The foregoing description of the Sales Agreement is not complete and is qualified in its entirety by reference to the full text of the (a) Original Sales Agreement, a copy of which was filed as an exhibit to the Company’s Current Report on Form 8-K filed with the SEC on November 7, 2024 and (b) the Sales Agreement Amendment, a copy of which is filed as an exhibit to this report, and each of which is incorporated herein by reference.

This report shall not constitute an offer to sell or the solicitation of an offer to buy any securities under the Sales Agreement, nor shall there be any sale of such securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

 

Exhibit No.

Description of Exhibit

1.1

 

Amendment No. 1 to At-The-Market Equity Offering Sales Agreement between ClearPoint Neuro, Inc. and Stifel, Nicolaus & Company, Incorporated, dated November 18, 2026

104

 

Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 


 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

 

CLEARPOINT NEURO, INC.

 

 

 

 

Date:

November 18, 2026

By:

/s/ Danilo D'Alessandro

 

 

 

Danilo D'Alessandro
Chief Financial Officer

 

 


Filing Exhibits & Attachments

2 documents

Keep reading